Regular purchasing channels for filgotinib and suggestions for preventing counterfeit drugs

Filgotinib (Filgotinib), as a selective JAK1 inhibitor, is mainly used to treat immune diseases such as rheumatoid arthritis. Since it has not been officially approved for marketing in my country, if patients need to use filgotinib, they usually need to purchase it through foreign channels. Formal purchasing channels mainly include internationally renowned pharmacies, officially authorized medical institutions, and reputable cross-border e-commerce platforms. Choosing formal channels can not only ensure the quality of medicines, but also avoid purchasing fake and shoddy products and ensure the safety of medication.

In foreign markets, filgotinib has two versions: original drug and generic version. The specification of the European version of the original drug is usually 200mg The price of the imitation version produced by Lucius is relatively affordable. A box of 100 mg × 30 tablets is priced at about 900 yuan. When making a choice, patients should reasonably choose a version of the drug that suits them based on their own financial situation and doctor's advice.

To prevent the purchase of counterfeit drugs, patients should focus on the packaging integrity, batch number information and drug authorization certificates. The packaging of regular drugs must be clearly printed and fully labeled, and the authenticity of the batch number should be verified through the manufacturer's official website or official authorized channels. In addition, avoid buying through purchasing agents or individual sellers of unknown origins to prevent the influx of counterfeit medicines, which may cause treatment risks and health damage.

In short, although filgotinib is not on the domestic market, patients can purchase original or generic drugs through regular international channels. When purchasing, you need to be careful to identify authenticity, give priority to guaranteed channels and brands, and strictly follow the doctor's medication instructions to ensure safe and effective treatment. In the future, with drug approval and market opening, we expect filgotinib to enter the country as soon as possible and provide patients with more convenient medication options.

Reference materials:https://www.drugs.com/